OncoSec Medical Inc. (OTCQB:ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present at five
events in September. The company’s agenda includes a number of
high-profile scientific and investment conferences.
Rodman and Renshaw 16th Annual Global Investment
Conference
Punit Dhillon, President and CEO, will present a corporate
overview of the company at the 16th Annual Rodman & Renshaw
Global Investment Conference, taking place at the New York Palace
Hotel in New York City, NY September 8-10, 2014. The presentation
will be held on Tuesday, September 9th in the Kennedy 1 Salon (4th
floor) at 10:25 AM ET.
At the time of the presentation, a live webcast will be
available via the following link:
http://wsw.com/webcast/rrshq24/oncs
OncoSec recommends registering at least 10 minutes prior to the
start of the presentation to ensure timely access. After the
presentation, an archived version of the webcast will be available
in the “Events” section of the OncoSec web page at
http://www.oncosec.com
Rodman & Renshaw 2014 Annual Global Investment Conference
will attract over 250 public and private companies from around the
world to present to an audience of over 2,000 engaged attendees.
The event will feature corporate presentations, Q&A sessions,
1-on-1 meetings and daily networking opportunities meant to
facilitate discussions between institutional investors, venture
capitalists, private equity firms, sophisticated private investors
and leading industry executives. For more information, please visit
http://www.rodm.com
Aegis Capital 2014 Healthcare and Technology
Conference
Punit Dhillon, President and CEO, will present a corporate
overview of the company at the 2014 Aegis Capital Healthcare and
Technology Conference, taking place September 10-13 at The Encore
at Wynn in Las Vegas, Nevada. The presentation will be held on
Thursday, September 11th in Room 2 at 9:45 AM PT.
The 2014 Healthcare and Technology Conference will showcase more
than 90 emerging and established companies in the healthcare and
technology sectors. The event will feature company presentations,
networking receptions and 1-on-1 investor meetings. For more
information, please visit http://www.aegiscapcorp.com
TEDx KPU
Tu Diep, Executive Director, Clinical Development, will present
a discussion titled, “The Miseducation of the Immune System“, at
TEDx KPU on September 27, 2014. The event will be hosted at
Kwantlen Polytechnic University (KPU) in Richmond, BC, Canada.
TEDx KPU will engage students, employees and the KPU community
in a day of discussion, education and narratives from a variety of
inspiring speakers aligned with the event’s theme, “Moment of
Genius”. These activities are designed to create an event that will
live up to the reputation of TED. The event will feature speakers
that reflect the dynamic and polytechnic characteristics of both
KPU and the Greater Vancouver area. For more information, please
visit http://www.ted.com/tedx/events/12634
Interface 2014 Digital Health Summit
Punit Dhillon, President and CEO, will attend and present at the
Interface 2014 Digital Health International Summit, taking place
September 29-30 at the Vancouver Convention Centre in Vancouver,
BC, Canada.
Interface 2014 Digital Health Summit is a two-day event designed
to engage, inform, inspire and connect digital health innovators
and other key stakeholders. This year’s summit will bring together
world-leading experts, innovators, disruptors and creative thinkers
to discuss the future of health. The event will include interactive
exhibits and forums, speaker presentations, educational seminars,
and networking activities meant to facilitate partnering and
collaboration. For more information, please visit
http://interfacesummit.com
Sachs 14th Annual Biotech in Europe Forum: For Global
Partnering & Investment
Robert Pierce, M.D., Chief Medical Officer, will present a
corporate overview of the company and participate in a panel
discussion titled, “Building the Cancer Focused Biotech”, at the
14th Annual Sachs Biotech in Europe Forum, taking place September
30th to October 1st at Congress Center Basel in Basel, Switzerland.
The panel discussion will begin at 12 PM CET on Tuesday, September
30th. The presentation will begin at 4:30 PM CET on Tuesday,
September 30th in the Darwin room.
At the time of the presentation, a live webcast will be
available via the events section of the OncoSec web page at
http://www.oncosec.com. OncoSec recommends registering at least 10
minutes prior to the start of the presentation to ensure timely
access. After the presentation, an archived version of the webcast
will be available on the website.
The Sachs Annual Biotech in Europe Forum is recognized as a
leading international stage for investing and partnering in the
biotech and life science industry. This year’s event will bring
together more than 100 presenting companies and over 600 delegates
to interact with leading investors, analysts, money managers and
pharma licensing executives in a highly transactional environment.
The forum will feature plenary panels, workshops, presentations,
and 1-on-1 meetings meant to facilitate networking and discussion
among attendees and participants. For more information, please
visit http://www.sachsforum.com/basel14/index.html
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
855-662-6732CFOinvestors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024